WuXi Biologics (Cayman) (FRA:1FW2) Construction In Progress: €1,285 Mil (As of Dec. 2025)


FRA:1FW2 WuXi Biologics (Cayman) Inc FRA:1FW2
99 GF Score
Price €3.83
GF Value €4.30
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is WuXi Biologics (Cayman) Construction In Progress?

WuXi Biologics (Cayman) FRA:1FW2 -1.79% 99 Construction In Progress is €1,285 Mil as of Dec. 2025. GuruFocus rates FRA:1FW2 with a GF Score™ of 99/100 and a GF Value™ of €4.30 (Modestly Undervalued). The stock has 3 warning signs investors should review.

WuXi Biologics (Cayman)'s quarterly construction in progress declined from Dec. 2024 (€1,280 Mil) to Jun. 2025 (€0 Mil) but then increased from Jun. 2025 (€0 Mil) to Dec. 2025 (€1,285 Mil).

WuXi Biologics (Cayman)'s annual construction in progress declined from Dec. 2023 (€1,766 Mil) to Dec. 2024 (€1,280 Mil) but then increased from Dec. 2024 (€1,280 Mil) to Dec. 2025 (€1,285 Mil).

WuXi Biologics (Cayman) Construction In Progress Historical Data

* Premium members only.

The historical data trend for WuXi Biologics (Cayman)'s Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WuXi Biologics (Cayman) Construction In Progress Chart

WuXi Biologics (Cayman) Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,510.73 2,157.67 1,765.84 1,279.53 1,285.32

WuXi Biologics (Cayman) Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,765.84 0.00 1,279.53 0.00 1,285.32
FRA:1FW2
99GF Score
WuXi Biologics (Cayman) Inc FRA:1FW2
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WuXi Biologics (Cayman) Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €1,285 Mil mean?
WuXi Biologics (Cayman) (FRA:1FW2) has a Construction In Progress of €1,285 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on WuXi Biologics (Cayman) and its competitors.
Is WuXi Biologics (Cayman)'s Construction In Progress too high?
WuXi Biologics (Cayman)'s current Construction In Progress is €1,285 Mil. Overall, WuXi Biologics (Cayman) has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Construction In Progress compare to VRTX and REGN?
WuXi Biologics (Cayman)'s Construction In Progress of €1,285 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current Construction In Progress is €1,285 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (FRA:1FW2) is currently considered Modestly Undervalued. The stock's GF Value™ is €4.30, compared to a current price of €3.83 — trading 10.9% below its estimated fair value. The current Construction In Progress is €1,285 Mil. WuXi Biologics (Cayman)'s overall GF Score™ is 99/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For WuXi Biologics (Cayman) (FRA:1FW2), the current Construction In Progress is €1,285 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WuXi Biologics (Cayman) (FRA:1FW2) Overvalued in 2026?

Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued. The current stock price of €3.83 is trading 10.9% below its estimated GF Value™ of €4.30. GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.

Key valuation signals for FRA:1FW2:

  • Construction In Progress: €1,285 Mil
  • GF Value™: €4.30 vs. price of €3.83 (10.9% below fair value)
  • GF Score™: 99/100 with 3 warning signs

No single metric tells the full story. See the FRA:1FW2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WuXi Biologics (Cayman) Business Description

Address No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
99GF Score

Get the complete analysis for FRA:1FW2

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.83
Price
€4.30
GF Value